عنوان مقاله [English]
Parkinson's disease (PD) is considered as a movement disorder, and its diagnosis is based on the presence of a set of cardinal motor symptoms. Since the pathogenesis of PD is not well understood today, the importance of the use of animal models to better understand PD and its cure is discovered. We aimed to provide new evidence on the comparison effect of rotenone on the components of PD. Thirty male mice (30±2 gr) were randomly divided into 3 groups; control group, rotenone solvent group, and rotenone group (ROT). ROT was treated with rotenone injections (2 mg/kg/48 h) for 19 days. Thus, the components of balance, movement, muscle rigidity and muscle strength tested by rotarod, open-field, and triple horizontal bar, and save testing data to evaluate and compare the effects of rotenone on these components. Component of muscle strength in all groups affected more than other components (P<0.05). In the next degree of balance, movement and muscle rigidity were affected. Rotenone could affect components of PD model which improved muscle strength component and was better than that of the other components. Probably this subject, including the main features of rotenone creates an experimental model of Parkinson's disease.
1. Alexander G.E. 2004. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in Clinical Neuroscience, 6(3): 259-280.
4. Beitz J.M., 2014. Parkinson's disease: a review. Front Bioscience (Schol Ed), 6: 65-74.
5. Bertram L., Tanzi R.E., 2005. The genetic epidemiology of neurodegenerative disease. Journal of Clinical Investigation, 115(6): 1449-1457.
7. Dauer W., Przedborski S., 2003. Parkinson's disease: mechanisms and models. Neuron, 39(6): 889-909.
9. Goetz C.G., 2011. The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harbor Perspectives in Medicine, 1(1): a008862.
10. Hatami H, Dehghan G., 2016. The Effect of Ethanolic The effect of ethanolic extract of Saffron (Crocus sativus L.) on improving the spatial memory parameters in the experimental models of Parkinson disease in male rats. Journal of Fasa University of Medical Sciences, 5(4): 534-541
11. Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., Kohsaka S., Yagi T., Yuasa S., 2006. Fyn is required for haloperidol-induced catalepsy in mice. The Journal of Biological Chemistry, 281(11): 7129-7135.
13. Jin H., Arthi K., Anamitra G., 2014. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease, 1842(8): 1282-1294.
14. Ogawa N., 1994. Levodopa and dopamine agonists in the treatment of Parkinson’s disease: advantages and disadvantages. European Neurology, 34(Suppl. 3): 20-28.
21.Tolosa, E., Tolosa E.L., Martí M.J., Valldeoriola F., Molinuevo J.L., 1998. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology, 50(6 Suppl 6): S2-S10.